Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Aclarion Inc (ACONW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ACONW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -80.36% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.21 | 52 Weeks Range 0.01 - 0.10 | Updated Date 06/28/2025 |
52 Weeks Range 0.01 - 0.10 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7855.96% |
Management Effectiveness
Return on Assets (TTM) -35.44% | Return on Equity (TTM) -72.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 582330 |
Shares Outstanding - | Shares Floating 582330 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Aclarion Inc
Company Overview
History and Background
Aclarion Inc. is a medical device company focused on technologies for diagnosing musculoskeletal pain. The company was founded to develop and commercialize technologies for detecting early lumbar disc disease.
Core Business Areas
- Nociscan: Aclarion's flagship product, Nociscan, is a Magnetic Resonance Spectroscopy (MRS) based technology used to identify painful spinal discs. It differentiates pain generating discs from those that are not based on biochemical composition.
Leadership and Structure
Details on Aclarion Inc.'s leadership team and organizational structure are not readily available in common financial databases. Further research into the company's filings and website would be required.
Top Products and Market Share
Key Offerings
- Nociscan: Nociscan utilizes MRS to assess the biochemical composition of spinal discs, aiming to improve diagnostic accuracy for lower back pain. Specific market share data or revenue figures for Nociscan are not publicly available. Competitors include traditional MRI diagnostic methods, discography, and other pain management approaches such as surgery. Companies involved in spinal diagnostics and treatments could be considered indirect competitors.
Market Dynamics
Industry Overview
The market for spinal diagnostics and pain management is large and growing, driven by an aging population and increasing prevalence of back pain. Advancements in minimally invasive techniques and diagnostic accuracy are key trends.
Positioning
Aclarion Inc. is positioned as a technology innovator seeking to improve diagnostic accuracy in spinal pain management. Their competitive advantage lies in utilizing MRS to provide biochemical information about spinal discs, rather than relying solely on anatomical imaging.
Total Addressable Market (TAM)
The global spinal surgery and pain management market is estimated to be billions of dollars. Aclarion Inc. is positioned to capture a portion of this market by improving the diagnostic accuracy of spinal pain and reducing unnecessary surgeries. Specific TAM for Nociscan is not publicly available.
Upturn SWOT Analysis
Strengths
- Innovative MRS technology
- Potential to improve diagnostic accuracy
- Focus on a large and growing market
Weaknesses
- Limited commercialization to date
- Requires specialized MRI equipment
- Relatively small company size
Opportunities
- Partnerships with hospitals and imaging centers
- Expansion into other musculoskeletal applications
- Increased adoption of personalized medicine approaches
Threats
- Competition from established diagnostic methods
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
Competitive Landscape
Assessment of Aclarion Inc.'s competitive advantages and disadvantages is limited without detailed competitor information.
Growth Trajectory and Initiatives
Historical Growth: Unable to assess historical growth without financial data.
Future Projections: Future growth projections are not publicly available without analyst reports and financial forecasts.
Recent Initiatives: Details on recent strategic initiatives undertaken by Aclarion Inc. are not readily available in common financial databases. Further research into the company's filings and website would be required.
Summary
Aclarion Inc. is an innovative medical device company with the potential to improve diagnostic accuracy in spinal pain management. However, its small size and limited commercialization pose challenges. Successful partnerships and market adoption will be crucial for future growth. Securing reimbursements for the Nociscan system will be a factor.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Public domain information
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. The financial data may not be readily available and may require further company and/or filing analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aclarion Inc
Exchange NASDAQ | Headquaters Broomfield, CO, United States | ||
IPO Launch date 2022-04-22 | CEO, President & Director Mr. Brent Ness | ||
Sector Healthcare | Industry Health Information Services | Full time employees 5 | Website https://www.aclarion.com |
Full time employees 5 | Website https://www.aclarion.com | ||
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and data transfer products, including AMBRA Healthcare, an imaging data transfer platform and NOCIWEB, a custom developed web-interface. In addition, it offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.